HLX301
As of the edition of 20 October 2026, HLX301 is a drug known only by a code name: of no established status; acts on CD274 and TIGIT.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Status not established
- Kind
- Code name only
- Registered trials
- 2, 0 stopped early
- Disease areas
- Cancer; Blood and lymph; Immune system; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 2 | 0 | 0 | 0 |
| All trials | 2 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Henlius Biotech | Lead sponsor of trials | 2022 to now |